RxDoctor Payments Data

Abigail Fowler

Optometrist · Claremore, OKNPI 1013021567

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 43.7% of the total. 2025 is the largest year on record at $159, 6.3 times the $25 reported in 2020. That places this record below the midpoint for optometrist clinicians in OK, where the typical reported total is $560.

$437in general payments, 2019–2025

Across 22 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$191
  • AbbVie$82
  • Tarsus Pharmaceuticals, Inc.$56
  • Alcon$47
  • Sun Pharmaceutical Industries Inc.$31
  • Johnson & Johnson Vision Care, Inc.$31

What the payments were for

  • Food & beverage$437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$437 in reported general payments places this provider in the 45th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$56,333
Medicare patients
327
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$55,014
MieboPerfluorohexyloctane/Pf12$10,385
LumiganBimatoprost18$7,622
Tobramycin-DexamethasoneTobramycin/Dexamethasone30$1,214
Latanoprost60$298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$82$62,63662 claims
Bausch & Lomb Americas Inc.Miebo$191$10,38512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Claremore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →